- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02488044
A Phase 1/2 Study of AEB1102 in Patients With Arginase 1 Deficiency
A Phase 1/2 Open-label Study in Patients With Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
A Phase 1/2 Open-label Study in Patients with Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102. This study is designed to evaluate the safety and tolerability of IV administration of AEB1102 for the treatment of pediatric and adult patients with Arginase 1 deficiency and hyperargininemia. This study will be conducted in 2 parts: Part 1 (Single Ascending Dose Escalation) and Part 2 (Repeated Dosing). Each part will be preceded by a baseline assessment of arginine levels. All patients who participate in Part 1 may continue AEB1102 dosing in Part 2 if they qualify for continued dosing. A data safety monitoring board (DSMB) will provide independent review of study safety data and recommend whether the sponsor should continue the study as planned, modify the study protocol, or discontinue the study.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
California
-
Stanford, California, Förenta staterna, 94305
- Stanford University School of Medicine
-
-
Florida
-
Gainesville, Florida, Förenta staterna, 32611
- University of Florida
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Children's Hospital of Michigan
-
-
New York
-
New York, New York, Förenta staterna, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75390
- UTSW
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Seattle Children's Hospital
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Porto, Portugal
- Centro Hospitalar S. Joao
-
-
-
-
-
London, Storbritannien
- Great Ormond Street Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male or female ≥ 2 years
- Documented diagnosis of Arginase 1 deficiency
- Adequate organ function as defined by laboratory assessment
- If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
- If a sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
- Patient or legal guardian is able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification) prior to any screening procedures
Exclusion Criteria:
- Transfusion of ≥ 2 units of RBCs within 60 days
- Active infection requiring systemic treatment
- Known infection with HIV, Hep B or Hep C
- Unstable hyperammonemia requiring hospitalization within 14 days
- Has a history of hypersensitivity to PEG or any other component of the AEB1102 (Co-ArgI-PEG) formulation
- If female, is lactating or breast feeding
PART 2 INCLUSION CRITERION:
1. Did not experience any safety or tolerability event in Part 1 which would preclude continued participation and dosing of AEB1102
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: AEB1102
AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks. Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy. |
modified human arginase I
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Participants With Adverse Events Related to ECGs
Tidsram: Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
The primary means of assessing ECG results was through assessing AEs related to ECGs. |
Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
|
Number of Participants With Adverse Events Related to Clinical Laboratory Results
Tidsram: Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
The primary means of assessing clinical laboratory results was through assessing AEs related to clinical laboratory results. Laboratory studies included hematology, chemistry, urinalysis, and coagulatio. |
Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pharmacokinetic Profile of IV AEB1102: Time of the Maximum Observed Concentration (Tmax)
Tidsram: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Through the Time of the Last Measurable Concentration (AUC0-t)
Tidsram: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Maximum Observed Concentration (Cmax)
Tidsram: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Apparent Terminal Elimination Half-life (T1/2)
Tidsram: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Extrapolated to Infinity (AUC0-∞)
Tidsram: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Serum Clearance (CL)
Tidsram: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Volume of Distribution (Vss)
Tidsram: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Plasma Arginine Concentrations After AEB1102 IV
Tidsram: 168 hrs post dose, Part 2: Change from Baseline to 8 weeks
|
Plasma arginine concentration post dose AEB1102 IV |
168 hrs post dose, Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: Guanidinoacetic Acid (GAA)
Tidsram: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: α-keto-δ-guanidinovaleric Acid (GVA)
Tidsram: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: Argininic Acid (ARGA)
Tidsram: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: N-α-acetyl-L-arginine (NAA)
Tidsram: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studierektor: Mattias Rudebeck, PhD MSc BMedSc, Immedica Pharma AB
Publikationer och användbara länkar
Allmänna publikationer
- Diaz GA, Schulze A, McNutt MC, Leao-Teles E, Merritt JL 2nd, Enns GM, Batzios S, Bannick A, Zori RT, Sloan LS, Potts SL, Bubb G, Quinn AG. Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency. J Inherit Metab Dis. 2021 Jul;44(4):847-856. doi: 10.1002/jimd.12343. Epub 2021 Jan 26.
- Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metab. 2005 Mar;84(3):243-51. doi: 10.1016/j.ymgme.2004.11.004. Epub 2004 Dec 19.
- Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol. 2011 Jun;4(3):138-46. doi: 10.1593/tlo.10265. Epub 2011 Jun 1.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Beräknad)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Metabolism, medfödda fel
- Genetiska sjukdomar, medfödda
- Metaboliska sjukdomar
- Hjärnsjukdomar, metabola, medfödda
- Hjärnsjukdomar, metaboliska
- Aminosyrametabolism, medfödda fel
- Ureacykelstörningar, medfödd
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Närings- och metabola sjukdomar
- Hyperargininemi
Andra studie-ID-nummer
- CAEB1102-101A
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .